Vincenzo Nasca, Research fellow at Memorial Sloan Kettering Cancer Center, shared on X:
“Neoadjuvant BOT with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.
Congrats to my colleague (and one of my best friends) Filippo Ghelard for this huge work, led by mentor Filippo Pietrantonio – massive team effort!”
Title: Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
Authors: Filippo Ghelardi, Margherita Ambrosini, Alessandra Raimondi, Andrei Tyshevich, Federica Palermo, Francesca Bergamo, Vincenzo Nasca, Paolo Manca, Ilaria Mulas, Lisa Derosa, Gina Brown, Claudia Chiodoni, Massimo Di Maio, Samantha Di Donato, Anna Chiaramonte, Lorenzo Castagnoli, Stephanie Ni, Darryl Nousome, Erik Spickard, Antony Tin, Robert Lentz, Adham Jurdi, Giovanna Sabella, Daniele Spada, Stefano Tamberi, Alessandro Passardi, Federica Morano, Emiliano Tamburini, Chiara Rossi, Luca Azzolin, Francesco Cambuli, Antonia Martinetti, Elisa Sottotetti, Andrew Allan Almonte, Valerio Iebba, Chiara Ratti, Riccardo Cerantola, Özlem Kutlu, Eleonora Cristarella, Serenella M. Pupa, Cecilia Villa, Eleonora Perissinotto, Margherita Galassi, Andrea Barina, Fabrizio Vittadello, Marcello Guaglio, Gianluca Baiocchi, Andrea Sartore-Bianchi, Riccardo Rosati, Chiara Cremolini, Isacco Montroni, Sara Lonardi, Andrea Sottoriva, Filippo Pietrantonio.
You can also read: UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer
